Twenty-six patients with metastatic malignant melanoma were treated with dimethyl triazeno imidazole carboxamide (DTIC), at a dose of 250 mg/m' intravenously daily for 5 days every 3 weeks. Six of 26(23%) patients achieved partial remission with a median response duration of 15 weeks. The median survival from onset of thereapy was 28 weeks for all patients and 45 weeks for those who responded to chemotherapy. Toxicity was acceptable and easily controlled.